Skip to content
天士力生物
|中文|English
  • Homepage
  • About Us
    • Company Profile
    • Chairman’s Message
    • Mission and Vision
    • Board of Directors
    • Management Team
    • Contact Us
  • Product Center
    • Marketed Products
    • Pipeline
    • Clinical Recruitment
    • About PUK
  • R&D and Innovation
    • R&D Approach
    • R&D Platform
    • R&D  Team
    • Cooperation
  • Commercialization Capabilities
    • Manufacturing Process
    • Quality Management
    • Precision Marketing
  • News Center
  • Careers
    • Corporate Culture
    • Job Opportunities
  • Homepage
  • About Us
    • Company Profile
    • Chairman’s Message
    • Mission and Vision
    • Board of Directors
    • Management Team
    • Contact Us
  • Product Center
    • Marketed Products
    • Pipeline
    • Clinical Recruitment
    • About PUK
  • R&D and Innovation
    • R&D Approach
    • R&D Platform
    • R&D  Team
    • Cooperation
  • Commercialization Capabilities
    • Manufacturing Process
    • Quality Management
    • Precision Marketing
  • News Center
  • Careers
    • Corporate Culture
    • Job Opportunities

A leading innovative

biopharmaceutical company in China

  • Media Reports
  • Company News
Menu
  • Media Reports
  • Company News

Tasly Biopharma signed license agreement with Sutro to introduce new ADC drug STRO-002

Read More »

CCTV: Tasly Accelerates Its Drug Research and Development to Build a Line of Defense for Health

Read More »

Tasly Biopharma ranks second in the 2019 Future Healthcare VB 100 -Top 100 China Innovative Medicine List

Read More »
Copyright © 2021 All Rights Reserved 天士力生物医药股份有限公司


沪ICP备 2021005430号-2


互联网药品信息服务资格证书编号(沪)-非经营性-2021-0008
Search for: